Equities

Alaunos Therapeutics Inc

TCRT:NAQ

Alaunos Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.76
  • Today's Change-0.06 / -2.13%
  • Shares traded9.02k
  • 1 Year change-86.32%
  • Beta-0.5561
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

  • Revenue in USD (TTM)7.00k
  • Net income in USD-19.13m
  • Incorporated2005
  • Employees1.00
  • Location
    Alaunos Therapeutics Inc2617 Bissonnet St, Suite 225HOUSTON 77005United StatesUSA
  • Phone+1 (617) 259-1970
  • Fax+1 (617) 241-2855
  • Websitehttps://alaunos.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Creative Medical Technology Holdings Inc17.00k-5.73m4.17m4.00--0.5484--245.59-4.07-4.070.0125.690.00151.00--4,250.00-51.83-110.00-53.71--60.0065.82-33,716.41-7,961.1420.20--0.00---89.84-40.8647.88------
Azitra Inc408.20k-9.96m4.19m10.00--0.3059--10.27-12.12-12.120.11511.800.0595--1.8340,820.00-145.30---194.72-------2,440.46------0.0191--141.55--6.02------
Lixte Biotechnology Holdings Inc0.00-4.03m4.23m3.00---------1.83-1.830.000.99860.00----0.00-139.98-104.18-163.33-111.05-----------563.880.00------19.41------
Enveric Biosciences Inc0.00-10.59m4.24m7.00--0.6924-----3.67-3.670.000.68620.00----0.00-133.67-104.94-206.10-156.88-------243.54----0.00------7.14------
Galera Therapeutics Inc0.00-29.11m4.30m7.00---------0.5892-0.58920.00-2.540.00----0.00-90.03-83.69-119.01-97.54-----------14.3411.60------5.05---29.84--
Notable Labs Ltd313.00k-16.74m4.34m16.00--0.6037--13.86-2.47-2.470.0460.74390.0176----19,562.50-93.89-52.02-120.26-62.0937.7060.19-5,346.97-3,636.93----0.0405---52.89-11.9365.13---50.69--
Synaptogenix Inc0.00-3.45m4.39m5.00--0.2229-----3.89-3.890.0014.990.00----0.00-5.54-40.33-6.89-43.36------------0.00-------142.17---3.21--
Alaunos Therapeutics Inc7.00k-19.13m4.42m1.00--1.17--631.35-11.95-11.950.00442.360.0004--1.757,000.00-117.34-74.83-143.58-89.57-----273,271.40-10,508.06----0.00---99.83-49.086.86---15.56--
Palisade Bio Inc0.00-14.17m4.45m9.00--0.3653-----20.07-20.070.0010.300.00----0.00-90.97-132.36-109.07-165.45-------27,892.32---972.730.0339-----0.781413.74--18.53--
Oncternal Therapeutics Inc1.85m-35.97m4.53m27.00--0.2875--2.45-12.19-12.190.62545.320.0495----68,370.37-96.40-49.40-116.52-54.51-----1,948.70-1,342.98----0.00---47.32--10.62------
Qualigen Therapeutics Inc0.00-9.27m4.57m4.00---------1.66-1.750.00-0.4450.00----0.00-134.64-----------------9.64--------10.22------
CNS Pharmaceuticals Inc0.00-15.97m4.60m3.00---------134.04-134.040.00-2.970.00----0.00-358.12-132.47---185.75---------------------23.42------
Pasithea Therapeutics Corp0.00-16.37m4.61m8.00--0.2853-----14.98-14.990.0015.490.00----0.00-58.66---62.74--------------0.00-------32.23------
Data as of Sep 20 2024. Currency figures normalised to Alaunos Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

13.85%Per cent of shares held by top holders
HolderShares% Held
MSD Partners LPas of 30 Jun 2024101.01k6.31%
The Vanguard Group, Inc.as of 30 Jun 202462.41k3.90%
BlackRock Fund Advisorsas of 30 Jun 202422.24k1.39%
Geode Capital Management LLCas of 30 Jun 202416.36k1.02%
SSgA Funds Management, Inc.as of 30 Jun 20245.02k0.31%
UBS Securities LLCas of 30 Jun 20244.47k0.28%
Commerce Bank (Investment Management)as of 30 Jun 20242.91k0.18%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 20242.90k0.18%
Osaic Wealth, Inc. (Investment Management)as of 30 Jun 20242.42k0.15%
Magnolia Capital Advisors LLCas of 30 Jun 20242.06k0.13%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.